Back to search results

Research on NNC0662-0419 with Birth Control and Stomach Emptying

This study is looking at how a new drug called NNC0662-0419 works when taken with birth control pills (Altavera) and acetaminophen (a common pain reliever). Researchers want to understand how NNC0662-0419 affects how your body handles these other medications and how quickly your stomach empties. This study is for women aged 18 to 64 who are not able to become pregnant, have overweight or obesity, and are generally healthy. The goal is to see if NNC0662-0419 is safe and effective when used with these other drugs. The study aims to enroll 45 participants, but its current status is unclear.

Study design
This is an interventional study involving 45 participants. Participants will receive all three treatments: NNC0662-0419, Altavera, and acetaminophen.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at Day 8 and 1 day after the last NNC0662-0419 dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07525791

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Recruiting
PHASE1Ages 18–64InterventionalTreatment
Novo Nordisk A/S
~45 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:NNC0662-0419Oral contraceptiveAcetaminophen

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area under curve (AUC) 0-24 h, EE, steady state (SS): The area under the EE plasma concentration-time curve (pre-dose to 24 hours post-dose)
Measured over Day 8 and 1 day after last NNC0662-0419 dose
+1 more outcome measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female (sex assigned at birth) of non-childbearing potential.
Age 18-64 years (both inclusive) at the time of signing the informed consent.
Body weight more than or equal to (≥) 60.0 kilogram (kg).
Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion

Known or suspected hypersensitivity to study intervention(s) or related products.
Use of any medication containing glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), or amylin receptor agonism before screening.
Any contraindications for the use of the oral contraception used in the study according to the Altavera Product Information.
Use of hormone replacement therapy within 28 days before screening or intention to initiate treatment with hormone replacement therapy during the study.
Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.
Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.
History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.

What this trial measures

  • Area under curve (AUC) 0-24 h, EE, steady state (SS): The area under the EE plasma concentration-time curve (pre-dose to 24 hours post-dose)Day 8 and 1 day after last NNC0662-0419 dose

    Measured as picograms per milliliter (h\*pg/mL)

  • AUC0-24h, LN, SS: The area under the LN plasma concentration-time curve (pre-dose to 24 hours post-dose)Day 8 and 1 day after last NNC0662-0419 dose

    Measured as h\*pg/mL